Publication:
Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season.

Thumbnail Image

Files

SecondSeasonImpactNirsevimab_2025.pdf (379.53 KB)
Identifiers
URI: https://hdl.handle.net/20.500.12105/27697
DOI: 10.1097/INF.0000000000004920

Publication date

2025-10-01

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publishers

Metrics
Google Scholar
Export
MarcXML METS

Research Projects

Organizational Units

Journal Issue

Abstract

Nirsevimab provides passive immunization against respiratory syncytial virus, yet concerns exist regarding its long-term impact. This study analyzed respiratory syncytial virus-associated lower respiratory tract infection severity in hospitalized children immunized with nirsevimab more than 6 months prior. No significant differences were found compared with nonimmunized children. Findings suggest no increased risk in the following season, supporting nirsevimab's safety as a preventive strategy.

Description

Keywords

Antibody-dependent enhancement Immunization Nirsevimab Respiratory syncytial virus

MeSH Terms

Antibodies, Monoclonal, Humanized Antiviral Agents Child Child, Preschool Female Humans Infant Male Respiratory Syncytial Virus Infections Respiratory Syncytial Virus, Human Seasons Treatment Outcome

DeCS Terms

Bibliographic citation

González-Bertolín, I., Alcolea, S., Alonso, P., Arroyas, M., Fernández Castiella, I., Echavarren, I., Iglesias-Caballero, M., Casas, I., García-García, M. L., & Calvo, C. (2025). Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season. Pediatric Infectious Disease Journal, 44(10), 1009–1011. https://doi.org/10.1097/INF.0000000000004920.

Collections

Centro Nacional de Microbiología (CNM)

Publisher version

https://doi.org/10.1097/INF.0000000000004920

Related dataset

Related publication

Document type

research article